gsk-933776
mAbexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2007 (NCT00459550)
Timeline
Indications
Mechanism of action
- Beta amyloid A4 proteinBINDING AGENT
Beta amyloid A4 protein binding agent
Neutralises disease-relevant aggregated forms of amyloid-beta.
Binds with high affinity to the Abeta N terminus (aa1-5).
- Beta amyloid A4 proteinINHIBITOR
APP inhibitor
APP other
Neutralises disease-relevant aggregated forms of amyloid-beta.
Binds with high affinity to the Abeta N terminus (aa1-5).
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109300 ↗
Also known as
- gsk933776
- gsk933776
- gsk-933776
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02033668 | Phase 1 | Jan 22, 2014 | GlaxoSmithKline, IQVIA |
| NCT01342926 | Phase 2 | Jun 1, 2011 | GlaxoSmithKline |
| NCT01424436 | Phase 1 | May 19, 2010 | GlaxoSmithKline |
| NCT00459550 | Phase 1 | Mar 1, 2007 | GlaxoSmithKline |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 4 | 4 | 2 | 2007 |
| IQVIA | For profit | 1 | 0 | 1 | 2014 |
2 organizations
Page 1 / 1